BioSpace News Archive

*Seraphic Group, the fast-growing, future-thinking health and technology company on a mission to restore our planet’s natural cycles of human health and ecology, today announces that its best-selling RESTORE line of products that promote gut-brain health is now ION*Biome

Greenwood Genetic Center utilizes Emedgene’s AI to slash turnaround times, improve diagnostic yield and return answers to patients faster. Emedgene’s platform automates much of the genomic analysis workflow, allowing Greenwood to reduce time-per-test by 75%.

John McLaughlin, Ph.D., has transitioned from ChanceLight Executive Vice President to a member of the Board of Directors.

Global law firm Goodwin announced today that Lily Wound has joined its Technology and Life Sciences practices as a partner in the New York office.

Inotrem S.A. announced a €39 million Series B financing led by Morningside Ventures, joined by Invus with participation from existing investors Andera Partners, Sofinnova Partners and BiomedInvest.

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2019.

Hollins Communications Research Institute (HCRI), a national center for stuttering research and therapy innovation, just completed another research initiative in collaboration with the National Institutes of Health (NIH).

NI Research is pleased to announce that the September/October issue of NeuroPerspective has been released. It features our comprehensive annual review of the Alzheimer’s space, including an assessment of the current conceptual trends vis-a-vis pathophysiology and therapeutic targets.

Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced the formation of its Scientific Advisory Board (SAB), which is comprised of industry experts in inflammatory and dermatological disease drug development.